16 November 2020: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases Posted at h in Press release Read More
20 February 2019: Calypso Biotech BV secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases. Posted at h in Press release Click to see full press release... Read More
19 February 2019: AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002 Posted at h in Press release Click to see full press release... Read More
31 March 2018: Calypso Biotech supports EUREOS Posted at h in News EUREOS is the European association for clinicians and researchers to share knowledge on Eosinophilic Esophagitis. http://eureos.online... Read More
31 March 2017: Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma Posted at h in Press release Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody. Read More